Hale David F - Jan 21, 2025 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role: Director
Signature: /s/ Gerald T. Proehl, Attorney-in-Fact
Stock symbol: DRMA
Transactions as of: Jan 21, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/23/2025, 05:00 PM
Previous filing: Jan 14, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRMA	Common Stock	Award		+78.7K	+3553.29%		81K	Jan 23, 2025	By Hale BioPharma Ventures LLC	F1, F2, F4
holding	DRMA	Common Stock						314	Jan 21, 2025	Direct
holding	DRMA	Common Stock						50	Jan 21, 2025	By Hale Trading Company L.P.	F4
holding	DRMA	Common Stock						148	Jan 21, 2025	By Hale Family Trust	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRMA	Warrant (Right to Buy)	Award		+78.7K			78.7K	Jan 21, 2025	Common Stock	78.7K	$1.27	By Hale BioPharma Ventures LLC	F1, F2, F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares of Common Stock and accompanying Warrant were purchased by the Reporting Person from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2	The purchase price per share of Common Stock and accompanying Warrant was $1.27.
F3	The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
F4	Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.